Fusion Antibodies plc

LSE FAB.L

Fusion Antibodies plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 3.50 M

Fusion Antibodies plc Net Cash Used Provided By Financing Activities is USD 3.50 M for the year ending March 31, 2024, a 40,397.40% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Fusion Antibodies plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 8.63 K, a 114.29% change year over year.
Fusion Antibodies plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -60.42 K, a -101.65% change year over year.
Fusion Antibodies plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 3.67 M, a 1,820.32% change year over year.
Fusion Antibodies plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD -213.43 K, a -491.85% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

LSE: FAB.L

Fusion Antibodies plc

CEO	Dr. Adrian Robert Kinkaid Ph.D.
IPO Date	Dec. 18, 2017
Location	United Kingdom
Headquarters	1 Springbank Road
Employees	27
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

Key trends

Past 5 years